Chimerix ( (CMRX) ) has released its Q4 earnings. Here is a breakdown of the information Chimerix presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimerix is a biopharmaceutical company focused on developing medicines to improve and extend the lives of patients with deadly diseases, with a key focus on treatments for glioma.
In its latest financial report, Chimerix announced significant developments, including the FDA’s acceptance of its New Drug Application for dordaviprone, a treatment for recurrent glioma, and its pending acquisition by Jazz Pharmaceuticals.
Financially, Chimerix reported a net loss of $23 million for the fourth quarter of 2024, an increase from the previous year, driven by higher research and development expenses and preparations for commercial launches. For the full year, the company recorded a net loss of $88.4 million, with research and development costs rising to $74.6 million. Despite these losses, the company maintains a strong capital position with $140.1 million available to fund operations.
The acquisition by Jazz Pharmaceuticals, valued at approximately $935 million, is expected to close in the second quarter of 2025, potentially enhancing Chimerix’s ability to bring dordaviprone to market.
Looking ahead, Chimerix is poised for a transformative year with the potential approval of dordaviprone and the strategic benefits anticipated from its acquisition by Jazz Pharmaceuticals.